A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors
Study Status
Closed to Enrollment
Study Description
The purpose of this study is to assess the safety and determine the maximum tolerated dose of the combination of BSI-201 with chemotherapeutic regimens in patients with advanced solid tumors.
Patients will receive Gemcitabine via i.v. infusion once weekly for 3 weeks out of 4 and BSI-201 twice weekly for the first 3 weeks of a 4 week cycle. Safety and efficacy assessments and procedures include physical exams and laboratory safety assessments, radiographic tumor response (CT/MRI scans), and exploratory testing.
Disease Status and/or Stage
Metastatic Pancreatic Cancer
Sponsor
BiPar Sciences
Key Eligibility
- Men and women age 18 and older
- Diagnosed with pancreatic cancer, whose disease has spread to other areas of the body
- Additional eligibility criteria discussed when you contact the study team
Principal Investigator
Contact
- June Greenberg, RN
- (212) 746-2651
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]